The biosimilars journey: current status and ongoing challenges

about

The biosimilars journey: current status and ongoing challenges

Item

http://www.wikidata.org/entity/Q57298628

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

The biosimilars journey: current status and ongoing challenges

@en

The biosimilars journey: current status and ongoing challenges

@nl

type

Item

label

The biosimilars journey: current status and ongoing challenges

@en

The biosimilars journey: current status and ongoing challenges

@nl

prefLabel

The biosimilars journey: current status and ongoing challenges

@en

The biosimilars journey: current status and ongoing challenges

@nl

P1476

The biosimilars journey: current status and ongoing challenges

@en

P2093

Daniel Egg Neto

http://www.w3.org/2001/XMLSchema#string

Igor Age Kos

http://www.w3.org/2001/XMLSchema#string

Sérgio Cândido Kowalski

http://www.w3.org/2001/XMLSchema#string

Valderílio Feijó Azevedo

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology

Clinical trial development for biosimilars

Regulatory considerations in oncologic biosimilar drug development

Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars?

Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data.

Switch from infliximab to infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseasesResponse to: Nikiphorou E, Kautiainen H, Hannonen P, et al. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used a

Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician.

Recommendations on how to ensure the safety and effectiveness of biosimilars in Latin America: a point of view

The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries

Pharmacovigilance Considerations for Biosimilars in the USA

P304

212543

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.7573/DIC.212543

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30302115

http://www.w3.org/2001/XMLSchema#string

P921

Farmakologi

molecular medicine

P932

6172013

http://www.w3.org/2001/XMLSchema#string